Bayer's cPSA test fares well against tPSA
German drugmaker Bayer AG has welcomed data published in the April issue of the Journal of Urology that show its complexed Prostate Specific Antigen (cPSA) test methodogoly was better than the conventional total Prostate Specific Antigen (tPSA) procedures. Leverkeusen-headquartered Bayer noted that the cPSA test discovered more men with a high risk of cancer. In addition, the scientists calculated that using the cPSA instead of the tPSA test made it possible to reduce the number of required biopsies more than 10%. Bayer concluded that an elevated level of cPSA was a better indicator of prostate cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze